


MYLS22

## Chemical Properties

CAS No. : 306959-01-3  
 Formula: C<sub>24</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S  
 Molecular Weight: 443.52  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
*Actual storage temperature shall be subject to the COA.*



## Biological Description

Description	MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity.
Targets(IC50)	Others
In vivo	MYLS22 (10 mg/kg/die;?peritumoral injection;?every 2 days for 14 days) causes the tumor growth curtailed mice

## Solubility Information

Solubility	DMSO: 45 mg/mL (101.46 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2547 mL	11.2734 mL	22.5469 mL
5 mM	0.4509 mL	2.2547 mL	4.5094 mL
10 mM	0.2255 mL	1.1273 mL	2.2547 mL
50 mM	0.0451 mL	0.2255 mL	0.4509 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Stéphanie Herkenne, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481